MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

AbbVie Inc

Healthcare US ABBV

200.99USD
11.54(6.09%)

Last update at 2024-10-30T18:56:00Z

Day Range

188.54202.35
LowHigh

52 Week Range

128.24162.75
LowHigh

Fundamentals

  • Previous Close 189.45
  • Market Cap273093.71M
  • Volume5643010
  • P/E Ratio42.38
  • Dividend Yield4.01%
  • EBITDA27993.00M
  • Revenue TTM55138.00M
  • Revenue Per Share TTM31.17
  • Gross Profit TTM 41527.00M
  • Diluted EPS TTM3.65

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 13477.00M 12989.00M 3398.00M 8426.00M 5197.00M
Minority interest -9.00000M -7.00000M 6.00M 21.00M 21.00M
Net income 11836.00M 11542.00M 4616.00M 7882.00M 5687.00M
Selling general administrative 15260.00M 12349.00M 11299.00M 6942.00M 7399.00M
Selling and marketing expenses - - - - -
Gross profit 40640.00M 38751.00M 30417.00M 25827.00M 25035.00M
Reconciled depreciation 8467.00M 8521.00M 6471.00M 2017.00M 1765.00M
Ebit 18117.00M 17924.00M 476.00M 12983.00M 6383.00M
Ebitda 26584.00M 26445.00M 6947.00M 13795.00M 8148.00M
Depreciation and amortization 8467.00M 8521.00M 6471.00M 812.00M 1765.00M
Non operating income net other -2596.00000M -2551.00000M -5685.00000M -3048.00000M -42.00000M
Operating income 18117.00M 17924.00M 476.00M 12983.00M 6383.00M
Other operating expenses 39240.00M 37311.00M 33243.00M 19898.00M 25946.00M
Interest expense 2230.00M 2384.00M 2280.00M 1509.00M 1144.00M
Tax provision 1632.00M 1440.00M -1224.00000M 544.00M -490.00000M
Interest income 186.00M 39.00M 174.00M 275.00M 204.00M
Net interest income -2044.00000M -2384.00000M -2280.00000M -1509.00000M -1144.00000M
Extraordinary items - - - - -86.00000M
Non recurring 697.00M 962.00M 1198.00M 385.00M 424.00M
Other items - - - - -
Income tax expense 1632.00M 1440.00M -1224.00000M 544.00M -490.00000M
Total revenue 58054.00M 56197.00M 45804.00M 33266.00M 32753.00M
Total operating expenses 21826.00M 19865.00M 17856.00M 12459.00M 18228.00M
Cost of revenue 17414.00M 17446.00M 15387.00M 7439.00M 7718.00M
Total other income expense net -3293.00000M -3513.00000M 2922.00M -4557.00000M -466.00000M
Discontinued operations - - - - -
Net income from continuing ops 11845.00M 11549.00M 4622.00M 7882.00M 5687.00M
Net income applicable to common shares 11836.00M 11542.00M 4616.00M 7882.00M 5687.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 138805.00M 146529.00M 150565.00M 89115.00M 59352.00M
Intangible assets 67439.00M 75951.00M 82876.00M 18649.00M 21233.00M
Earning assets - - - - -
Other current assets 4401.00M 4993.00M 3562.00M 2354.00M 1895.00M
Total liab 121518.00M 131093.00M 137468.00M 97287.00M 67798.00M
Total stockholder equity 17254.00M 15408.00M 13076.00M -8172.00000M -8446.00000M
Deferred long term liab 2190.00M 3009.00M 3646.00M 1130.00M 1067.00M
Other current liab 22468.00M 19817.00M 17883.00M 10380.00M 10385.00M
Common stock 18.00M 18.00M 18.00M 18.00M 18.00M
Capital stock 18.00M 18.00M 18.00M 18.00M 18.00M
Retained earnings 4784.00M 3127.00M 1055.00M 4717.00M 3368.00M
Other liab 31716.00M 30982.00M 30401.00M 18476.00M 15557.00M
Good will 32156.00M 32379.00M 33124.00M 15604.00M 15663.00M
Other assets 4834.00M 4081.00M 5144.00M 1913.00M 1208.00M
Cash 9201.00M 9746.00M 8449.00M 39924.00M 7289.00M
Cash and equivalents - - - - -
Total current liabilities 29538.00M 35194.00M 28661.00M 15585.00M 17239.00M
Current deferred revenue - - - - -
Net debt 54070.00M 66938.00M 77607.00M 26804.00M 33021.00M
Short term debt 4136.00M 12495.00M 8502.00M 3753.00M 5308.00M
Short long term debt 4136.00M 12495.00M 8502.00M 3753.00M 5308.00M
Short long term debt total 63271.00M 76684.00M 86056.00M 66728.00M 40310.00M
Other stockholder equity 14651.00M 15162.00M 15120.00M -9311.00000M -9352.00000M
Property plant equipment 4935.00M 5110.00M 5248.00M 2962.00M 2883.00M
Total current assets 28463.00M 27928.00M 24173.00M 49519.00M 16945.00M
Long term investments 241.00M 277.00M 293.00M 93.00M 1420.00M
Net tangible assets -82341.00000M -96202.00000M -102924.00000M -42425.00000M -45342.00000M
Short term investments 28.00M 84.00M 30.00M 0.00000M 772.00M
Net receivables 11254.00M 9977.00M 8822.00M 5428.00M 5384.00M
Long term debt 59135.00M 64189.00M 77554.00M 62975.00M 35002.00M
Inventory 3579.00M 3128.00M 3310.00M 1813.00M 1605.00M
Accounts payable 2934.00M 2882.00M 2276.00M 1452.00M 1546.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 33.00M 28.00M 21.00M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2199.00000M -2899.00000M -3117.00000M -3596.00000M -2480.00000M
Additional paid in capital - - - - -
Common stock total equity 18.00M 18.00M 18.00M 18.00M 18.00M
Preferred stock total equity - - - - -
Retained earnings total equity 4784.00M 3127.00M 1055.00M 4717.00M 3368.00M
Treasury stock -4594.00000M -3143.00000M -2264.00000M -24504.00000M -24108.00000M
Accumulated amortization - - - - -
Non currrent assets other 3381.00M 1875.00M 1205.00M 1158.00M 141.00M
Deferred long term asset charges - - - - -
Non current assets total 110342.00M 118601.00M 126392.00M 39596.00M 42407.00M
Capital lease obligations - - - - -
Long term debt total 59135.00M 64189.00M 77554.00M 62975.00M 35002.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -447.00000M -1398.00000M 114.00M 981.00M -368.00000M
Change to liabilities 2147.00M 338.00M 941.00M -1121.00000M 190.00M
Total cashflows from investing activities -623.00000M -2344.00000M -37557.00000M 596.00M -1006.00000M
Net borrowings -12433.00000M -8414.00000M -2703.00000M 25823.00M 3189.00M
Total cash from financing activities -24803.00000M -19039.00000M -11501.00000M 18708.00M -14396.00000M
Change to operating activities -264.00000M -197.00000M 134.00M 97.00M -499.00000M
Net income 11845.00M 11549.00M 4622.00M 7882.00M 5687.00M
Change in cash -545.00000M 1297.00M -31475.00000M 32635.00M -2014.00000M
Begin period cash flow 9746.00M 8449.00M 39924.00M 7289.00M 9303.00M
End period cash flow 9201.00M 9746.00M 8449.00M 39924.00M 7289.00M
Total cash from operating activities 24943.00M 22777.00M 17588.00M 13324.00M 13427.00M
Issuance of capital stock - - - - -
Depreciation 8467.00M 8521.00M 6471.00M 2017.00M 1765.00M
Other cashflows from investing activities 519.00M -159.00000M -36873.00000M 167.00M 167.00M
Dividends paid -10043.00000M -9261.00000M -7716.00000M -6366.00000M -5580.00000M
Change to inventory -686.00000M -142.00000M -40.00000M -231.00000M -226.00000M
Change to account receivables -1455.00000M -1321.00000M -929.00000M -74.00000M -591.00000M
Sale purchase of stock -1487.00000M -934.00000M -978.00000M -629.00000M -12014.00000M
Other cashflows from financing activities 1160.00M -674.00000M -333.00000M -552.00000M -104.00000M
Change to netincome 2646.00M 4029.00M 6389.00M 4754.00M 6677.00M
Capital expenditures 695.00M 787.00M 798.00M 552.00M 638.00M
Change receivables -1455.00000M -1321.00000M -929.00000M -74.00000M -591.00000M
Cash flows other operating 1979.00M -197.00000M 134.00M 97.00M -75.00000M
Exchange rate changes - -97.00000M -5.00000M 7.00M -39.00000M
Cash and cash equivalents changes -483.00000M 1297.00M -31475.00000M 32635.00M -2014.00000M
Change in working capital -258.00000M -1322.00000M 106.00M -1329.00000M -1126.00000M
Stock based compensation 671.00M 692.00M 753.00M 430.00M 421.00M
Other non cash items 6149.00M 4235.00M 7961.00M 3624.00M 6256.00M
Free cash flow 24248.00M 21990.00M 16790.00M 12772.00M 12789.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABBV
AbbVie Inc
11.54 6.09% 200.99 42.38 13.68 4.88 22.14 5.72 31.93
LLY
Eli Lilly and Company
-72.079 7.98% 831.50 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson
0.53 0.33% 160.62 29.17 14.33 3.74 5.18 3.80 15.22
MRK
Merck & Company Inc
0.77 0.74% 104.50 59.83 12.33 4.50 6.47 4.94 23.79
AZN
AstraZeneca PLC ADR
-2.075 2.76% 73.14 38.69 16.31 4.67 5.46 5.20 17.74

Reports Covered

Stock Research & News

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Key Executives

Name Title Year Born
Mr. Richard A. Gonzalez Chairman & CEO 1954
Mr. Robert A. Michael Vice Chairman & Pres 1970
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer 1963
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer 1969
Mr. Scott T. Reents Exec. VP & CFO 1967
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations 1963
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer 1962
Ms. Elizabeth Shea VP of Investor Relations NA
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec. NA
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.